Replies to post #272529 on Avid Bioservices Inc (CDMO)

[NoMoDo]

It was abused to pay the BOD of a failing penny stock selling for $.3x a share more than most Fortune 500 companies.

If you say it long enough, it must be true. Except when it is false:

Forbes magazine reported that the average total compensation for a Fortune 500 CEO as of the 2012 Fortune survey was $10.5 million

But this is not how execs make their big money. Most is made through exercising stock options. In addition to their paycheck:

The average boss realized $5.6 million from exercising options last year.

Richard D. Fairbank Richard D. Fairbank , chief executive of Capital One Financial , was the top earner in 2005. Fairbank?s $249.3 million in total pay came almost entirely from exercised stock options.

[biopharm]

Your opinion is totally flawed, beginning with Avid. Avid is about to do things no other small biotech has accomplished and at that time it is when most will realize that without Avid there is no Peregrine and without Pererine there is no Avid.

The days where it was cost effective for a small biotech to outsource manufacturing is not over.....because that is what must happen MOST times for a normal situation and a hopeful drug to bring to market.

Peregrine is not, though... the average small biotech, and I think you are well aware of this.

Paradigm shifts about to make a new fault line right in the middle of Big Pharma and depending on which side one is on will mean the difference of remaining competitive in IO combo treatments or falling behind and never able to regroup.